

ASX Announcement
18 December 2019

***Regeneus receives innovation grant from the Department of
Industry, Innovation and Science***

Regeneus Ltd (ASX: RGS) (“**Regeneus**” or “**the Company**”), a clinical-stage regenerative medicine company, has received \$50K in funding as part of the Innovation Connections Grant from the Australian Government’s Department of Industry, Innovation and Science. The grant has been awarded to the Company under the Department’s Entrepreneurs’ Programme for Regeneus’ study with Monash University, which explores the mode of action of mesenchymal stem cells (MSCs) in pain management. The funding matches Regeneus’ project spending over 12 months.

The Innovation Connections Grant aims to help collaboration between businesses and research organisations to develop and implement new ideas with commercial potential.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: 02 9237 2805
E: WE-AURegeneus@we-worldwide.com